Whittier Trust Co. of Nevada Inc. Sells 836 Shares of Eli Lilly and Company $LLY

Whittier Trust Co. of Nevada Inc. decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,604 shares of the company’s stock after selling 836 shares during the quarter. Eli Lilly and Company makes up 1.0% of Whittier Trust Co. of Nevada Inc.’s portfolio, making the stock its 18th largest position. Whittier Trust Co. of Nevada Inc.’s holdings in Eli Lilly and Company were worth $49,589,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. bought a new stake in Eli Lilly and Company during the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares in the last quarter. 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares in the last quarter. Miller Global Investments LLC bought a new stake in Eli Lilly and Company during the 4th quarter valued at about $33,000. Finally, Hopwood Financial Services Inc. lifted its holdings in Eli Lilly and Company by 113.6% during the 3rd quarter. Hopwood Financial Services Inc. now owns 47 shares of the company’s stock valued at $36,000 after buying an additional 25 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced it will acquire Kelonia Therapeutics to add an in‑vivo CAR‑T/gene‑delivery platform (KLN‑1010) that could materially expand its oncology pipeline and long‑term growth optionality. Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
• Positive Sentiment: UBS kept a Buy rating and $1,250 price target on LLY after the deal, signaling analyst confidence that the acquisition enhances Lilly’s growth runway. Eli Lilly: Kelonia Acquisition Expands Next‑Gen In‑Vivo CAR‑T Platform and Supports Buy Rating
• Positive Sentiment: Consensus analyst stance remains constructive (reported as a “Moderate Buy”), which supports buy‑side interest despite near‑term volatility. Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: The deal structure: $3.25B upfront with up to $7B total via milestones — strategic for pipeline but large enough to attract scrutiny on near‑term cash/deal economics. Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
• Neutral Sentiment: Media/industry reports tracked the deal’s progression over the weekend and Monday, so some price moves reflect news flow timing rather than a change in fundamentals. Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
• Negative Sentiment: Investors expressed caution about the timing/size of the deal as a hedge against potential GLP‑1 revenue normalization — some coverage framed the move as diversification away from high GLP‑1 reliance. Eli Lilly hedges for a GLP-1 revenue drop-off with $7B acquisition
• Negative Sentiment: Regulatory headlines add pressure: the FDA has requested additional data on Lilly’s newly approved obesity (GLP‑1) pill related to potential liver injury and post‑marketing cardiovascular studies, creating short‑term uncertainty. Eli Lilly (LLY) Says FDA Requests Additional Data on Obesity Pill
• Negative Sentiment: Some outlets noted an immediate negative price reaction as the Kelonia deal details emerged, reflecting investor wariness about pay‑up risk and near‑term dilution of focus/capital. Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here’s Why.

Analysts Set New Price Targets

LLY has been the subject of a number of research analyst reports. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Freedom Capital upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Barclays began coverage on shares of Eli Lilly and Company in a report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price target for the company. BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,224.59.

Eli Lilly and Company Stock Down 0.7%

NYSE:LLY opened at $920.62 on Tuesday. The company has a market cap of $869.82 billion, a PE ratio of 40.11, a P/E/G ratio of 1.08 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The company’s 50 day moving average is $968.67 and its two-hundred day moving average is $984.09.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 34.7 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.